The therapeutic efffect of Oncolytic recombinant Sendai Virus against refractory head and neck cancer.

• Project/Area Number: 26462626
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Otorhinolaryngology
• Research Institution: Kitasato University (2015-2017); National Defense Medical College (2014)
• Principal Investigator: Yamashita Taku 北里大学, 医学部, 教授 (00296683)
• Co-Investigator(Kenkyū-buntansha): 冨藤 雅之 防衛医科大学校(医学教育部医学科進学課程及び専門課程、動物実験施設、共同利用研究施設、病院並びに防衛, 病院 耳鼻咽喉科科, 講師 (80327626)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000); Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 遺伝子治療 / 頭頸部癌 / 同所移植モデル / センダイウイルス / 甲状腺癌 / 未分化癌

Outline of Final Research Achievements

We studied the tumor-surface uPA activity-dependent oncolytic recombinant Sendai virus (SeV), named BioKnife, for the treatment of ATC（anaplastic thyroid carcinoma).　In vitro, uPA activity in human ATC and oral cancer cell lines was measured using a colorimetric method. Cytotoxicity of BioKnife against these cell lines was evaluated by cell count reagent. In vivo, Orthotopic models were treated with intratumoral injections of each SeV vector and were observed daily until >20% weight loss developed. All three ATC cell lines showed a high level of uPA activity. BioKnife induced dose-dependent cytotoxicity in all the cell lines. In orthotopic models, treated with BioKnife showed suppression of tumor growth and prolonged survive days.These results encourage further clinical studies for this novel agent to treat this fetal carcinoma.

Research Products

• [Presentation] A novel treatment strategy for anaplastic thyroid carcinoma using urokinase-type plasminogen activator-dependent oncolytic recombinant Sendai virus (2017)
  • Author(s): Taku Yamashita, Yoshihiro Miyagawa, Akihiro Shiotani
  • Organizer: 2nd Congress of Asia-Pacific Society of Thyroid Surgery
  • Int'l Joint Research
• [Presentation] 腫瘍溶解性センダイウイルスによる頭頸部癌の新規治療 (2015)
  • Author(s): 宮川義弘, 山下拓, 田中伸吾, 田中雄也, 冨藤雅之, 荒木幸仁, 塩谷彰浩
  • Organizer: 第６７回日本気管食道科学会
  • Place of Presentation: ザ・セレクトン福島他（福島県福島市）
  • Year and Date: 2015-11-19
• [Presentation] A Urokinase-type Plasminogen Activator-dependent Oncolytic Sendai Virus, Eradicates Head and Neck Squamous Cell Carcinoma. (2015)
  • Author(s): Tanaka S, Yamashita T, Araki K, Tomufuji M, Kamide D, Miyagawa Y, Shiotani A
  • Organizer: 39th Annual Meeting of Japan society of Head and Neck Oncology
  • Place of Presentation: 神戸国際会議場（兵庫県神戸市）
  • Year and Date: 2015-06-03
  • Int'l Joint Research
• [Presentation] Bioknife, a urokinase-type plasminogen activator-dependent oncolytic Sendai Virus, exerminate orthotopic anaplastic thyroid carcinoma. (2014)
  • Author(s): Miyagawa Y, Yamashita T, Araki K, Tomufuji Y, Ueda Y, Yonematsu Y, Shiotani A
  • Organizer: IFHNOS 5th World Congress and AHNS 2014 meeting
  • Place of Presentation: New York
  • Year and Date: 2014-07-25 – 2014-07-30